Hassan S.

About Hassan S.

I am an Analyst in Health Policy at the Congressional Research Service (CRS), where I provide objective, nonpartisan policy analysis to the U.S. Congress on matters related to the regulation of medicinal products and public health emergency preparedness. My portfolio focuses on FDA oversight of human medical products, such as drugs, biologics, compounded drugs, over-the-counter drugs and controlled substances as well as the broader legal and regulatory frameworks that govern emergency use authorities, drug shortages, and the medical product supply chain. With dual doctorates in pharmacy (PharmD) and law (JD), I specialize in translating complex scientific, legal, and regulatory information into actionable insights for legislators and policymakers. I routinely advise congressional staff on legislative text, agency operations, statutory interpretation, and appropriations strategies related to the Food and Drug Administration and other HHS agencies. My work bridges science, law, and public policy—with particular attention to the evolving challenges of drug regulation, biomedical innovation, and public health emergency preparedness and response efforts. I also bring experience in evaluating FDA\'s administrative authorities, tracking user fee reauthorizations (e.g, PDUFA), and analyzing legislative proposals affecting FDA’s organizational structure and jurisdiction. I am especially interested in opportunities at the intersection of regulatory strategy, legislative affairs, and the future of healthcare policy—particularly those that leverage innovative artificial intelligence technologies.

Experience

1. Analyst in Health Policy

   Library of Congress

   Mar 2021 — Present · Washington, DC, US

   As an Analyst in Health Policy for CRS, I:Provide objective, nonpartisan analysis to Congress on the regulation of medicinal products under the FDCA, including prescription drugs, over-the-counter drugs, biologics, compounded products, and emerging therapies.Conduct legislative and regulatory analysis of FDA authorities related to product approval, postmarket surveillance, drug shortages, controlled substances, and Emergency Use Authorizations (EUAs).Monitor and evaluate trends in pharmaceutical innovation, federal agency reorganization, user fee programs (e.g, PDUFA), and appropriations for the FDA and related HHS entities.Prepare tailored reports, confidential memoranda, and briefings to support congressional oversight and legislative development.Serve as a subject matter expert on public health emergency preparedness and response, including federal coordination, supply chain resilience, and pandemic-related authorities.Engage regularly with congressional staff to provide timely, actionable policy insights on FDA-related legislation and regulatory strategy.Translate complex regulatory frameworks and scientific data into accessible, policy-relevant materials for a legislative audience.Perform rigorous policy research using legal, scientific, and government databases while ensuring fidelity to legislative intent and policy impact.

Education

• Albany College of Pharmacy and Health Sciences

  Doctor of Pharmacy - PharmD

  2006 — 2012

• University of Maryland Francis King Carey School of Law

  Juris Doctor (J.D.)

  2015 — 2018